Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Viral vectors for cancer vaccines or gene therapy offer a number of advantages, vaccine-based products are being restored based on gene and cell therapy and due to the introduction of next-generation transfer vectors including adenovirus, adeno-associated virus, and lentivirus. The quality and purity/efficacy of the vectors are the most important, and as part of the carrier test package, the determination of viral titer is a critical measurement.
Creative Biolabs utilizes powerful economical plate-based flow cytometry assays, plaque and endpoint dilution assays for viral titer determination to accurately optimize infection parameters for protein production in cell cultures for viral infection.
Plaque assays are classical bioassays used to measure viral infectivity in test articles and can be used to purify cloned virus populations or to determine viral titers to be per gram of plaque forming units (pfu/ml). We can count individual plaques obtained from virus stocks of different dilutions to determine the viral titer (pfu/ml) for a given transfusion or virus stock.
Endpoint dilution assays (EPDA) can be used in a variety of assays. Creative Biolabs can use 96-well plate EPDA instead of plaque assay and plaque purification as a means of determining viral titers or identifying and purifying recombinant viruses. The improved 12-well plate EPDA can be used as a routine method for viral titers determination; it can be used to estimate the efficiency of initial co-transfection, identify infected cells, approximate viral titers, and amplify viral titers.
An immunotitration method based on flow cytometry has been developed by Creative Biolabs to determine the infectious unit (IU) and transduction unit (TU) of the viral vector. This titration method counts infected cells by measuring the expression of viral proteins of TU of IU and transgenic proteins in individual cells after staining with fluorescent conjugated antibody. Its advantages are convenience, rapidity and accuracy.
The TCID50 assay (tissue culture infectious dose) is a quantitative assay system for determining viral titration. This procedure is performed to determine the infection titer of any virus that can cause cytopathic effect (CPE) in tissue culture, and to maintain the viability of cells in culture for 5 to 20 days.
For more details, please feel free to contact us for project quotations and more detailed information.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
